Discovery Life Sciences lanza servicios para el estudio de tumores sólidos FFPE y cfDNA TruSight Oncology 500 (TSO500) para avanzar en el desarrollo de biopsias líquidas e investigación clínica en inmunoterapia

By In The News
November 13, 2020 in The Headlines

Followers 0

Reply to this topic

Recommended Posts

In The News

Posted November 13, 2020

- Share

Posted November 13, 2020

HUNTSVILLE, Alabama, 13 de noviembre de 2020 /PRNewswire/ -- Discovery Life Sciences™ (Discovery), líder mundial en soluciones de biomuestras, servicios de genómica, celulares y de inmunohistoquímica (IHC), anuncia la incorporación de la tecnología TruSight Oncology 500 (TSO500) de...

View the full article

Quote

Link to comment

Share on other sites

Reply to this topic...

× Pasted as rich text. Paste as plain text instead

Only 75 emoji are allowed.

× Your link has been automatically embedded. Display as a link instead

× Your previous content has been restored. Clear editor

× You cannot paste images directly. Upload or insert images from URL.

Insert image from URL

Followers 0

Go to topic listing

Most Contributions
1. In The News
  201331
2. Jaydee
  13869
3. Kip Powick
  11831
4. deicer
  10837
5. dagger
  9572
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  251.2k
- Total Posts
  
  523.4k

Sign In

Discovery Life Sciences lanza servicios para el estudio de tumores sólidos FFPE y cfDNA TruSight Oncology 500 (TSO500) para avanzar en el desarrollo de biopsias líquidas e investigación clínica en inmunoterapia

Recommended Posts

In The News

Link to comment

Share on other sites

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support